Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23342727 | 0.73 | — | — | |
| SCHEMBL27172227 | 0.70 | — | — | |
| SCHEMBL12319503 | 0.69 | KDM4E (0.33) | MEN1LMNAMAPTKMT2AGAA | |
| SCHEMBL17146543 | 0.69 | KDM4E (0.33) | MEN1LMNAMAPTKMT2AGAA | |
| SCHEMBL1011491 | 0.68 | CREBBP (0.39) | MEN1KMT2ABRD4CREBBP | |
| SCHEMBL14200341 | 0.68 | MAOA (0.38) | MEN1LMNAMAPTKMT2A | |
| SCHEMBL24489433 | 0.68 | NISCH (0.33) | MEN1LMNAMAPTKMT2AHSD17B10 | |
| SCHEMBL14094059 | 0.66 | MEN1 (0.39) | MEN1LMNAMAPTKMT2AALOX5 | |
| SCHEMBL31440970 | 0.65 | GAA (0.38) | MAPTGAA | |
| SCHEMBL20707954 | 0.65 | NPC1 (0.40) | MEN1MAPTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021103317-A1 | HOLE TRANSPORT MATERIAL HAVING SPIROBISACRIDINE CORE AND ORGANIC LIGHT-EMITTING DIODE | 武汉华星光电半导体显示技术有限公司 | 2021-06-03 | — | — | WO | disclosed |
| EP-2758403-B1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9187439-B2 | Tricyclic compounds useful as neurogenic and neuroprotective agents | INCEPTION ORION, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | INCEPTION ORION, INC. | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243313-A1 | TRICYCLIC COMPOUNDS USEFUL AS NEUROGENIC AND NEUROPROTECTIVE AGENTS | BDNF, GAP43, NLN | MEN1 2655/4885LMNA 1827/4885MAPT 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.